sirolimushttp://www.unboundmedicine.com/medline/ebm/research/sirolimusUnbound MEDLINE is a service provided by Unbound Medicine, Inc. that includes data and services from the U.S. National Library of Medicine's MEDLINE® and PubMed® databases.en-usUnbound Medicine, Inc.Tubular Toxicity in Sirolimus- and Cyclosporine-Based Transplant Immunosuppression Strategies: An Ancillary Study From a Randomized Controlled Trial.http://www.unboundmedicine.com/medline/ebm/record/19926370/full_citation/Tubular_Toxicity_in_Sirolimus__and_Cyclosporine_Based_Transplant_Immunosuppression_Strategies:_An_Ancillary_Study_From_a_Randomized_Controlled_Trial_Franz S, Regeniter A, Hopfer H, et al. 
Tubular Toxicity in Sirolimus- and Cyclosporine-Based Transplant Immunosuppression Strategies: An Ancillary Study From a Randomized Controlled Trial. [JOURNAL ARTICLE]
Am J Kidney Dis 2009 Nov 16.
Abstract | Full Citation | Publisher Full Text | Find Related Articles No Association of Chromosome 9p21.3 Variation With Clinical and Angiographic Outcomes After Placement of Drug-Eluting Stents.http://www.unboundmedicine.com/medline/ebm/record/19926059/full_citation/No_Association_of_Chromosome_9p21_3_Variation_With_Clinical_and_Angiographic_Outcomes_After_Placement_of_Drug_Eluting_Stents_Hoppmann P, Erl A, Türk S, et al. 
No Association of Chromosome 9p21.3 Variation With Clinical and Angiographic Outcomes After Placement of Drug-Eluting Stents. [JOURNAL ARTICLE]
JACC Cardiovasc Interv 2009 Nov; 2(11):1149-1155.
Abstract | Full Citation | Find Related Articles Long-Term Risk of Adverse Outcomes and New Malignancies in Patients Treated With Oral Sirolimus for Prevention of Restenosis.http://www.unboundmedicine.com/medline/ebm/record/19926058/full_citation/Long_Term_Risk_of_Adverse_Outcomes_and_New_Malignancies_in_Patients_Treated_With_Oral_Sirolimus_for_Prevention_of_Restenosis_Kufner S, Hausleiter J, Ndrepepa G, et al. 
Long-Term Risk of Adverse Outcomes and New Malignancies in Patients Treated With Oral Sirolimus for Prevention of Restenosis. [JOURNAL ARTICLE]
JACC Cardiovasc Interv 2009 Nov; 2(11):1142-1148.
Abstract | Full Citation | Find Related Articles Lesion Complexity Determines Arterial Drug Distribution After Local Drug Delivery.http://www.unboundmedicine.com/medline/ebm/record/19925836/full_citation/Lesion_Complexity_Determines_Arterial_Drug_Distribution_After_Local_Drug_Delivery_Tzafriri AR, Vukmirovic N, Kolachalama VB, et al. 
Lesion Complexity Determines Arterial Drug Distribution After Local Drug Delivery. [JOURNAL ARTICLE]
J Control Release 2009 Nov 16.
Abstract | Full Citation | Find Related Articles Proteinuria after conversion to sirolimus in kidney transplant recipients: impact of pre-existing proteinuria, graft function, and angiotensin-converting enzyme inhibitors/angiotensin-receptor antagonists.http://www.unboundmedicine.com/medline/ebm/record/19925471/full_citation/Proteinuria_after_conversion_to_sirolimus_in_kidney_transplant_recipients:_impact_of_pre_existing_proteinuria_graft_function_and_angiotensin_converting_enzyme_inhibitors/angiotensin_receptor_antagonists_Marx C, Busch M, Ott U, et al. 
Proteinuria after conversion to sirolimus in kidney transplant recipients: impact of pre-existing proteinuria, graft function, and angiotensin-converting enzyme inhibitors/angiotensin-receptor antagonists. [JOURNAL ARTICLE]
Clin Transplant 2009 Nov 18.
Abstract | Full CitationSirolimus: A Novel Immunosuppressive Drug in Heart Transplantation.http://www.unboundmedicine.com/medline/ebm/record/19925439/full_citation/Sirolimus:_A_Novel_Immunosuppressive_Drug_in_Heart_Transplantation_Kurian KC, Addisu A 
Sirolimus: A Novel Immunosuppressive Drug in Heart Transplantation. [JOURNAL ARTICLE]
Recent Pat Cardiovasc Drug Discov 2009 Nov; 4(2):187-191.
Abstract | Full Citation | Find Related Articles Mortality and drug exposure in a 5-year cohort of patients with chronic liver disease.http://www.unboundmedicine.com/medline/ebm/record/19924579/full_citation/Mortality_and_drug_exposure_in_a_5_year_cohort_of_patients_with_chronic_liver_disease_Hug BL, Lipsitz SR, Seger DL, et al. 
Mortality and drug exposure in a 5-year cohort of patients with chronic liver disease. [JOURNAL ARTICLE]
Swiss Med Wkly 2009 Nov 19.
Abstract | Full CitationLymphangioleiomyomatosis: solitary abdominal manifestation (2009: 9b).http://www.unboundmedicine.com/medline/ebm/record/19921526/full_citation/Lymphangioleiomyomatosis:_solitary_abdominal_manifestation__2009:_9b__Possekel AK, Katenkamp D, Brambs HJ, et al. 
Lymphangioleiomyomatosis: solitary abdominal manifestation (2009: 9b). [JOURNAL ARTICLE]
Eur Radiol 2009 Dec; 19(12):3015-3018.
Abstract | Full CitationSirolimus-induced signaling modifications in Kaposi's sarcoma with resolution in a liver transplant recipient.http://www.unboundmedicine.com/medline/ebm/record/19919613/full_citation/Sirolimus_induced_signaling_modifications_in_Kaposi's_sarcoma_with_resolution_in_a_liver_transplant_recipient_Ho CM, Huang SF, Hu RH, et al. 
Sirolimus-induced signaling modifications in Kaposi's sarcoma with resolution in a liver transplant recipient. [JOURNAL ARTICLE]
Clin Transplant 2009 Nov 16.
Abstract | Full Citation | Find Related Articles Three-Dimensional Time-of-Flight Secondary Ion Mass Spectrometry Imaging of a Pharmaceutical in a Coronary Stent Coating as a Function of Elution Time.http://www.unboundmedicine.com/medline/ebm/record/19919043/full_citation/Three_Dimensional_Time_of_Flight_Secondary_Ion_Mass_Spectrometry_Imaging_of_a_Pharmaceutical_in_a_Coronary_Stent_Coating_as_a_Function_of_Elution_Time_Fisher GL, Belu AM, Mahoney CM, et al. 
Three-Dimensional Time-of-Flight Secondary Ion Mass Spectrometry Imaging of a Pharmaceutical in a Coronary Stent Coating as a Function of Elution Time. [JOURNAL ARTICLE]
Anal Chem 2009 Nov 17.
Abstract | Full Citation | Find Related Articles